PipelineHuidaGene has multiple R&D pipelines for ophthalmology and neurology.
-
01Neurology Diseases
MECP2 Duplication Syndrome (MDS)
Huntington's Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
-
02Ophthalmology Diseases
RPE65 Mutation-Associated Inherited Retinal Dystrophies (RPE65-IRD)
Neovascular Age-related Macular Degeneration (nAMD)
RHO-Associated Retinitis Pigmentosa (RHO-adRP)
-
03Neuromuscular Diseases
-
HuidaGene Presents Late-Breaking Data at World Muscle Society 2024 Demonstrating HG302 CRISPR/hfCas12Max DNA-Editing Therapy for Duchenne Muscular Dystrophy to Support M.U.S.C.L.E. Clinical TrialSep 24,2024
Learn More
-
HuidaGene Therapeutics Announces the Appointment of Dr. Xin Zhang as Chief Operations Officer and Chief Medical Officer to Further Strengthen the Management TeamSep 09,2024
Learn More
-
HuidaGene to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2024 Annual MeetingSep 02,2024
Learn More